目的 探讨血脂康胶囊联合替格瑞洛治疗稳定性冠心病的临床疗效。方法 选取2021年10月—2024年10月在合肥市第二人民医院接受治疗的120例稳定性冠心病患者，依据用药方案的差异将患者分为对照组和治疗组，每组各60例。对照组口服替格瑞洛片进行治疗，给药剂量为90 mg/次，每日2次；治疗组在对照组治疗基础上联合应用血脂康胶囊口服治疗，单次剂量为0.6 g，每日2次给药，均为餐后服用。两组患者均接受为期2个月的连续治疗。观察两组临床疗效，并比较治疗前后中医证候评分、西雅图心绞痛量表（SAQ）评分，24 h缺血发作次数和最长持续时间，血清脂蛋白相关磷脂酶A2（Lp-PLA2）、肌酸激酶同工酶MB（CK-MB）和细胞间黏附分子-1（ICAM-1）水平变化。结果 临床疗效分析显示，治疗组以95.00%的总有效率显著优于对照组的81.67%（P＜0.05）。治疗后，两组中医证候评分较前显著降低，而SAQ评分显著升高（P＜0.05）；治疗后，治疗组中医证候评分低于对照组，SAQ评分高于对照组（P＜0.05）。治疗后两组24 h监测显示缺血发作次数与单次最长持续时间均显著缩短（P＜0.05）；治疗后治疗组缺血发作次数与单次最长持续时间均低于对照组（P＜0.05）。治疗后两组Lp-PLA2、CK-MB及ICAM-1水平均呈现显著下降（P＜0.05）；治疗后，治疗组Lp-PLA2、CK-MB及ICAM-1水平低于对照组（P＜0.05）。结论 血脂康胶囊联合替格瑞洛治疗稳定性冠心病疗效显著，不但可显著改善患者心肌缺血症状和生活质量，而且能促进血清学指标的修复，具有重要临床推广价值。

Objective To evaluate the clinical efficacy of Xuezhikang Capsules combined with ticagrelor in treatment of stable coronary heart disease. Methods A total of 120 patients with stable coronary heart disease who were treated at Hefei Second People’s Hospital from October 2021 to October 2024 were selected. According to the differences in medication regimens, the patients were divided into control group and treatment group, with 60 cases in each group. Patients in control group were treated with oral Ticagrelor Tablets at a dose of 90 mg each time, twice daily. Patients in control group were combined with the oral administration of Xuezhikang Capsules on the basis of treatment in control group. The single dose was 0.6 g, administered twice daily, both after meals. Both groups of patients received continuous treatment for a period of two months. The clinical efficacy of two groups was observed, and the TCM syndrome score, SAQ score, the number of 24 h ischemic attacks and the longest duration, as well as the changes in the levels of serum Lp-PLA2, CK-MB, and ICAM-1 before and after treatment were compared. Results Clinical efficacy analysis showed that the treatment group had a total effective rate of 95.00%, which was significantly better than 81.67% in the control group (P < 0.05). After treatment, the TCM syndrome scores of both groups were significantly lower than before, but the SAQ scores were significantly increased (P < 0.05). After treatment, the TCM syndrome score of the treatment group was lower than that of the control group, and the SAQ score was higher than that of the control group (P < 0.05). 24 h Monitoring in both groups after treatment showed that the number of ischemic attacks and the maximum duration of a single attack were significantly shortened (P < 0.05). After treatment, the number of ischemic attacks and the longest duration of a single attack in the treatment group were both lower than those in the control group (P < 0.05). After treatment, the levels of Lp-PLA2, CK-MB, and ICAM-1 in both groups decreased significantly (P < 0.05). After treatment, the levels of Lp-PLA2, CK-MB, and ICAM-1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Xuezhikang Capsules combined with ticagrelor has a remarkable therapeutic effect on stable coronary heart disease, not only significantly improve the myocardial ischemia symptoms and life quality, but also promote the repair of serological indicators, which has important clinical promotion value.

R972

合肥市卫生健康委医学科研项目（Hwk2023zd009）